06Transparency / Outcomes

What our pilot cohort actually does, in aggregate.

Most clinics either show no outcome data or show only the best individual case. We publish the aggregate, including the things that did not work. The figures below are illustrative pilot data on a synthetic cohort — calibrated to plausible STEP-1 / SURMOUNT-1 ranges — while we collect consented real-world readouts for our Q3 2026 readout.

Notice · Synthetic illustrative cohort, n = 200 simulated. No real patient data. Replaced with consented real-world readout at Q3 2026.

Pilot

−11.3%

mean weight loss · wk 18

Pilot

84%

adherence at 12 weeks

Pilot

+59%

median IGF-1 from baseline

Pilot

9.5%

discontinuation for AE

Weight loss trajectory

% from baseline

Wk 0Wk 18

IGF-1 response (GHRP arm)

ng/mL median

Mo 0Mo 12

Response distribution at 18 weeks

≥ 15% loss (super-responder)22%

10–15% loss38%

5–10% loss26%

0–5% loss9%

< 0% (non-responder)5%

Adverse events leading to dose change

Persistent nausea12.4%
Constipation8.1%
Injection-site reaction3.2%
Lipase elevation (asymptomatic)1.5%
Suspected gallbladder symptoms0.8%
Discontinued for AE9.5%

Methodology

— Cohort is currently a parameterized simulation calibrated to STEP-1, SURMOUNT-1, and SCALE published distributions, with realistic dropout and AE rates.
— Real-world readout will replace these figures at Q3 2026 with IRB-reviewed methods and pre-registered endpoints.
— No patient-identifiable data has ever been used to populate this dashboard.
— Source code and parameter assumptions will be published on the formulary changelog when the real-world cut goes live.